301 related articles for article (PubMed ID: 33084153)
1. A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.
Thompson KM; Kalkowska DA; Badizadegan K
Risk Anal; 2021 Feb; 41(2):376-386. PubMed ID: 33084153
[TBL] [Abstract][Full Text] [Related]
2. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
[TBL] [Abstract][Full Text] [Related]
3. An economic analysis of poliovirus risk management policy options for 2013-2052.
Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM
BMC Infect Dis; 2015 Sep; 15():389. PubMed ID: 26404632
[TBL] [Abstract][Full Text] [Related]
4. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
[TBL] [Abstract][Full Text] [Related]
5. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
6. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G
PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638
[TBL] [Abstract][Full Text] [Related]
7. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
[TBL] [Abstract][Full Text] [Related]
8. An Updated Economic Analysis of the Global Polio Eradication Initiative.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):393-406. PubMed ID: 33590521
[TBL] [Abstract][Full Text] [Related]
9. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
[TBL] [Abstract][Full Text] [Related]
10. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM
Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925
[TBL] [Abstract][Full Text] [Related]
11. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
Duintjer Tebbens RJ; Thompson KM
Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767
[TBL] [Abstract][Full Text] [Related]
12. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis of post-polio certification immunization policies.
Sangrujee N; Cáceres VM; Cochi SL
Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
[TBL] [Abstract][Full Text] [Related]
14. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
[TBL] [Abstract][Full Text] [Related]
15. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
[TBL] [Abstract][Full Text] [Related]
16. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
[TBL] [Abstract][Full Text] [Related]
17. [Polio vaccines, eradication and posterradication].
Salmerón García F; Portela Moreira A; Soler Soneira M; López Hernández S; Chamorro Somoza Díaz-Sarmiento M; Pérez González I; Rubio Gómez MI; Pérez González A; Sagredo Rodríguez A; Ruiz Antúnez S; Timón Jiménez M; Frutos Cabanillas G
Rev Esp Salud Publica; 2013; 87(5):497-505. PubMed ID: 24322286
[TBL] [Abstract][Full Text] [Related]
18. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative.
Fine PE; Carneiro IA
Am J Epidemiol; 1999 Nov; 150(10):1001-21. PubMed ID: 10568615
[TBL] [Abstract][Full Text] [Related]
19. Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.
Badizadegan K; Kalkowska DA; Thompson KM
Med Decis Making; 2023; 43(7-8):850-862. PubMed ID: 37577803
[TBL] [Abstract][Full Text] [Related]
20. Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States.
Sutter RW; Prevots DR; Cochi SL
Pediatr Clin North Am; 2000 Apr; 47(2):287-308. PubMed ID: 10761505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
